Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial
Portfolio Pulse from
Moleculin Biotech, Inc. has received its first country approval in Europe to begin recruiting for its Phase 3 MIRACLE trial for treating R/R Acute Myeloid Leukemia. The trial will evaluate Annamycin in combination with Cytarabine. The company plans to start treating subjects in Q1 2025.
February 11, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moleculin Biotech has received regulatory approval in Europe to start recruiting for its Phase 3 MIRACLE trial for R/R AML, with plans to treat the first subject in Q1 2025. This marks a significant milestone in their clinical development.
The approval to begin recruiting for the Phase 3 trial is a critical step forward for Moleculin Biotech, indicating progress in their clinical development pipeline. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100